author-photo

Todd Fox

Novartis

58

Papers

799

Citations

Citation Trend

Filter By

Papers (42) Sort By

Journal Conference Others

THU0397 SYMPTOMS OF PERIPHERAL ARTHRITIS ARE SIGNIFICANTLY IMPROVED IN PATIENTS WITH ANKYLOSING SPONDYLITIS TREATED WITH SECUKINUMAB

2020 Annals of the Rheumatic Diseases
Show All
- Source
- Cite
- Save
Citations (1)
TNF-α antagonists differentially induce TGF-β1-dependent resuscitation of dormant-like Mycobacterium tuberculosis

2020 PLOS Pathogens
Show All
- Source
- Cite
- Save
Citations (12)
EP38 Secukinumab provides sustained improvement of enthesitis in patients with ankylosing spondylitis: pooled analysis of four pivotal Phase 3 studies

2020 Rheumatology
Show All
- Source
- Cite
- Save
Citations (0)
Long-term safety of secukinumab in patients with moderate-to-severe plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis: integrated pooled clinical trial and post-marketing surveillance data

2019 Arthritis Research & Therapy
Show All
- Source
- Cite
- Save
Citations (113)
Incidence rates of inflammatory bowel disease in patients with psoriasis, psoriatic arthritis and ankylosing spondylitis treated with secukinumab: a retrospective analysis of pooled data from 21 clinical trials

2019 Annals of the Rheumatic Diseases
Show All
- Source
- Cite
- Save
Citations (91)
Spinal radiographic progression over 2 years in ankylosing spondylitis patients treated with secukinumab: a historical cohort comparison

2019 Arthritis Research & Therapy
Show All
- Source
- Cite
- Save
Citations (17)
257 Secukinumab demonstrates a consistent safety profile with up to 5 years’ treatment in patients with psoriatic arthritis and moderate-to-severe plaque psoriasis: updated pooled safety analyses

2019 Rheumatology
Show All
- Source
- Cite
- Save
Citations (1)
SAT0315 STRUCTURAL DAMAGE PROGRESSION OVER 4 YEARS OF SECUKINUMAB TREATMENT IN ANKYLOSING SPONDYLITIS: POST-HOC ANALYSIS OF MEASURE-1 TRIAL USING A LONGITUDINAL BAYESIAN MIXTURE MODEL

2019 Annals of the Rheumatic Diseases
Show All
- Source
- Cite
- Save
Citations (0)
185 Secukinumab demonstrates consistent safety over long-term exposure in patients with psoriatic arthritis and moderate-to-severe plaque psoriasis: updated pooled safety analyses

2018 Rheumatology
Show All
- Source
- Cite
- Save
Citations (1)
184 Secukinumab provides sustained remission and low disease activity related to disease activity index for psoriatic arthritis: two year results from the FUTURE 2 study

2018 Rheumatology
Show All
- Source
- Cite
- Save
Citations (0)